%0 Journal Article
%T Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
%A Batty N
%A Kossoff E
%A Dy GK
%J Journal of Experimental Pharmacology
%D 2012
%I Dove Medical Press
%R http://dx.doi.org/10.2147/JEP.S26591
%X vestigational agents in metastatic basal cell carcinoma: focus on vismodegib Review (1224) Total Article Views Authors: Batty N, Kossoff E, Dy GK Published Date August 2012 Volume 2012:4 Pages 97 - 103 DOI: http://dx.doi.org/10.2147/JEP.S26591 Received: 05 April 2012 Accepted: 30 May 2012 Published: 31 August 2012 Nicolas Batty,1 Ellen Kossoff,2 Grace K Dy1 1Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA; 2Department of Pharmacy, Roswell Park Cancer Center, Buffalo, NY, USA Abstract: Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge ) is a novel first-in-human, first-in class, orally bioavailable Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the United States on January 2012. This signaling pathway is involved in the carcinogenesis of several types of tumor, as exemplified by basal cell carcinoma. This review focuses on the role of the Hedgehog pathway in the pathogenesis of basal cell carcinoma, the pharmacology and the clinical activity of vismodegib, as well as a brief summary of investigational agents in development targeting this pathway.
%K hedgehog inhibitors
%K metastatic basal cell carcinoma
%K hedgehog signalling pathway
%U https://www.dovepress.com/investigational-agents-in-metastatic-basal-cell-carcinoma-focus-on-vis-peer-reviewed-article-JEP